Main Article Content
OBJECTIVE: The aims and objectives of the study is to evaluate and analyze the effectiveness of anti viral drug, Remdesivir for the treatment of covid-19 patients in two population groups i.eNon-Obese and obese individuals with positive covid-19.
STUDY DESIGN: Randomized, placebo-controlled trial study.
SETTING: THQ Hospital Sambrial and THQ Hospital Wazirabad.
METHODOLOGY: The study is initiated in the outpatient department where the subjects complaining about the respiratory symptoms were further assessed for covid-19 laboratory examination. The patients with positive labs were included in the study. A clinical trial is conducted on three groups, a placebo category comprising of covid-19 patient not treated with remdesivir, obese category and non-obese category with positive covid-19 treated with remdesivir.
RESULTS: A total of 60 patients underwent randomization, with 40 assigned to remdesivir (20 in non obese category while 20 in obese group) and 20 participants to placebo. According to the clinical investigations, individuals who was administered remdesivir in non obese group, improved earlier with (95% confidence interval),while obese individuals recovered lately whereas those who received placebo showed no clinical significance statistically with (95 % confidence interval). Patients who got remdesivir in non obese population were shown to have a higher chance of clinical improvement than those who were in obese and placebo categories.
CONCLUSION: In this study, we examine the current evidence for remdesivir's effectiveness against COVID-19 and discuss the comparison between the two population groups and we evaluated the effectiveness of remdesivir in non obese in contrast with obese category. Non obese group showed better improvement than obese group, while control group shows no effect.To confirm these findings, more large-scale, randomised placebo-controlled clinical trials are needed.